Evaluation of efficacy, safety and tolerability...

In the News

IHI team engages with top brass at SERI

The IHI team (right) led by Dr. Honorati Masanja (not seen on the photo) meets with SERI officials (left row) during a stakeholder engagement meeting in Bern last week. PHOTO/COURTESY …

Health professionals learn “One Health” approach

Dr. Ally Olotu stresses a point when he addressed participants and invited guests during the opening ceremony. PHOTO/IHIcoms (Bagamoyo, Aprili 5 2019) Health professionals from Zoonotic disease risk areas of …

Recent Projects

Calcium supplementation on pregnant women

Project summary This is a trial-based study funded by the Bill and Melinda Gates Foundation. It intends to generate evidence for decision-making on the potential non-inferiority of a lower dose …

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

A Phase 3 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin plus PA‐824 plus Pyrazinamide after 4 and 6 months of Treatment in Adult Subjects with Drug‐Sensitive Smear‐Positive Pulmonary Tuberculosis and after 6 months of Treatment in Adult Subjects with Multi‐Drug Resistant, Smear‐Positive Pulmonary Tuberculosis (STAND Trial).

The STAND trial, sponsored by the Global Alliance for TB Drug Development (TB Alliance) is a multi-center and multi-country study with over 50 study sites across Africa, Asia, Eastern Europe and Latin America. The trial is on the new three-drug regimen PaMZ for both TB and MDR-TB patients. In Tanzania the study is done in four sites: IHI (PI, Dr. Francis Mhimbira), Mbeya Medical Research Center-NIMR (PI, Dr. Issa Sabi), Kilimanjaro Clinical Research Institute (KCRI)-Moshi (Prof. Blandina Mmbaga) and NIMR-Mwanza (PI, Dr. George Praygod). The STAND trial is expected to run for 4 years. It is a Phase 3 Open‐Label Partially Randomized Trial.

Lead Scientists:

Francis Mhimbira

Frederick Haraka

Partners

National Institute of Medical Research
Kilimanjaro Clinical Research Institute
TB Alliance

Funders

No items found

Projects Location

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016